
Assertio Therapeutics Settles for $3.6 Million Over Alleged False Claims Act Violations Linked to Fentanyl Marketing
Assertio Therapeutics, Inc., the pharmaceutical manufacturer previously known as Depomed, Inc., has agreed to a $3.6 million settlement over claims it violated the False Claims Act. Announced by the Justice Department on May 5, the company faced …